


**62.** A composition in pharmaceutical dosage form comprising an anticancer effective amount comprising a compound or pharmaceutically acceptable salt of claim **48**, in combination with a pharmaceutically acceptable carrier, additive, or excipient.

**63.** The composition of claim **62**, comprising a compound of the chemical structure



or a pharmaceutically acceptable salt thereof.

**64.** The composition according to claim **62**, wherein said UPA is human recombinant urokinase.

**65.** The composition according to claim **62** further comprising an additional anticancer agent.

**66.** The composition according to claim **65** wherein said additional anticancer agent is an antimetabolite, an inhibitor of topoisomerase I and II, an alkylating agent, a microtubule inhibitor or a mixture thereof.

**67.** The composition according to claim **65** wherein said additional anticancer agent is a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor,

a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhibitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase (mek) inhibitor, a VEGF trap antibody or a mixture of any of the foregoing agents.

**68.** A method of treating cancer in a patient in need comprising administered to said patient an effective amount of a composition according to claim **48**.

\* \* \* \* \*